Given that the impact of hypoxic TME on the efficacy of anti-tumor immunotherapy has not yet been considered, further research focus on the identification of potent SETDB1 inhibitors and analysis of their efficacy for hypoxic cancer cells, either alone or in combination with immunotherapy, should aid in the improvement of anti-cancer strategies. This evidence concerns the gene SETDB1 and cancer.